Tokio Marine Asset Management Co. Ltd. Buys 568 Shares of Eli Lilly and Company (NYSE:LLY)

Tokio Marine Asset Management Co. Ltd. raised its stake in Eli Lilly and Company (NYSE:LLY) by 1.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 47,809 shares of the company’s stock after purchasing an additional 568 shares during the quarter. Eli Lilly and Company comprises approximately 1.5% of Tokio Marine Asset Management Co. Ltd.’s holdings, making the stock its 11th biggest position. Tokio Marine Asset Management Co. Ltd.’s holdings in Eli Lilly and Company were worth $27,869,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of LLY. JGP Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 0.9% in the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after buying an additional 16 shares in the last quarter. Walkner Condon Financial Advisors LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after buying an additional 17 shares in the last quarter. Patton Albertson Miller Group LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after buying an additional 17 shares in the last quarter. Valley Wealth Managers Inc. boosted its stake in shares of Eli Lilly and Company by 1.3% during the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after purchasing an additional 17 shares during the period. Finally, Sandy Cove Advisors LLC boosted its stake in shares of Eli Lilly and Company by 0.8% during the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after purchasing an additional 17 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Down 1.8 %

Shares of NYSE:LLY traded down $13.49 during trading hours on Wednesday, hitting $732.20. The company’s stock had a trading volume of 2,052,626 shares, compared to its average volume of 3,038,542. Eli Lilly and Company has a 52 week low of $370.68 and a 52 week high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company has a market capitalization of $695.71 billion, a price-to-earnings ratio of 126.24, a P/E/G ratio of 1.59 and a beta of 0.34. The firm’s fifty day moving average price is $763.40 and its 200 day moving average price is $664.52.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.09 EPS. As a group, research analysts expect that Eli Lilly and Company will post 12.52 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on LLY shares. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday, April 15th. Barclays lifted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Citigroup lifted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.